BIIB Stock - Biogen Idec Inc.

BIIB Stock Chart

BIIB Profile

Biogen Inc. is a prominent biotechnology firm renowned for its comprehensive efforts in discovering, developing, manufacturing, and distributing therapies aimed at treating a spectrum of neurological and neurodegenerative diseases. At the forefront of its product offerings are innovative treatments for multiple sclerosis (MS), including widely recognized brands such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. These medications play pivotal roles in managing the symptoms and progression of MS, addressing critical needs within the patient community.

Beyond MS, Biogen expands its therapeutic impact with SPINRAZA, a breakthrough treatment for spinal muscular atrophy (SMA), and FUMADERM, indicated for plaque psoriasis. Additionally, the company has made significant strides in the realm of biosimilars, offering alternatives referencing prominent biologics like ENBREL, HUMIRA, and REMICADE across various therapeutic indications.

Biogen maintains a robust pipeline of products under development, focusing on advancing treatments not only in MS and neuroimmunology but also in challenging areas such as Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropathic pain, and immunology-related conditions. The company's commitment to innovation is further bolstered by strategic collaborations and license agreements with key industry players, including Acorda Therapeutics, Eisai Co., Ltd., and Sage Therapeutics. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen continues to drive forward its mission of pioneering therapies that enhance the quality of life for patients worldwide, reaffirming its pivotal role in the biotechnology landscape.

BIIB Revenue Chart

BIIB Earnings

Analyst Ratings